Novartis Halts Lupus Nephritis Trial of Fabhalta; AstraZeneca Signs AI Deal With insitro

· Health · Switzerland · United Kingdom

Novartis terminated a mid-stage trial of Fabhalta, also known as iptacopan, in lupus nephritis, citing "strategic considerations" in a federal clinical trials database. Fabhalta is a key part of Novartis' portfolio and had delivered $505 million in sales. The move removes a near-term readout from a drug the company has been expanding into multiple indications. In a separate development, AstraZeneca struck an AI drug discovery deal with California-based insitro, paying $40 million upfront in return for access to insitro's technology. The two items illustrate contrasting forces in pharma R&D: pipeline pruning at one large company and continued investment in AI-driven discovery at another.

Why it matters：The halted lupus nephritis study trims a potential indication for a key Novartis drug, while AstraZeneca's AI deal shows large pharma continuing to pay for discovery platforms, together reflecting how pipelines are being reshaped by both pruning and technology bets.

Key points

  • Novartis ended a mid-stage Fabhalta trial in lupus nephritis, citing strategic considerations in a federal database.
  • Fabhalta, also known as iptacopan, is a key Novartis asset that had generated $505 million in sales.
  • AstraZeneca will pay insitro $40 million upfront in an AI drug discovery collaboration.

Sources (original reporting)

More stories from this day